3D Mammogram (Tomosynthesis) Denied by Insurance? Here's How to Appeal

Digital breast tomosynthesis (DBT) — commonly called 3D mammography — is a significant improvement over conventional 2D mammography. It detects up to 41% more invasive cancers and substantially reduces false-positive call-backs that require additional imaging. Yet insurance coverage for 3D mammography remains inconsistent, and many women receive unexpected bills when their insurer decides to cover only the 2D component and bill the 3D "add-on" separately.

What Is 3D Mammography and Why Does It Matter?

Conventional digital mammography (2D FFDM) captures two flat images of each breast. Digital breast tomosynthesis (3D/DBT) acquires multiple low-dose X-ray images at different angles and reconstructs them into a series of thin "slices," allowing radiologists to view breast tissue layer by layer.

The clinical advantages are substantial:

• Better cancer detection: Multiple studies, including the JAMA tomosynthesis landmark study, show 41% more invasive cancers detected compared to 2D alone
• Fewer false positives: The recall rate for additional imaging is reduced by 15–40%
• Especially valuable for dense breasts: In women with dense breast tissue, 3D imaging significantly improves lesion visibility

The ACR now recommends 3D mammography as the preferred mammographic technique for screening.

How the 3D Billing Problem Works

When a facility performs a combined 2D+3D mammogram, it is typically billed using two codes:

• CPT 77067: Screening mammography, bilateral (2D)
• CPT 77063: Screening digital breast tomosynthesis (3D add-on)

Some insurers cover CPT 77067 (the 2D component) as a fully covered ACA preventive service but treat CPT 77063 (the 3D add-on) as an optional upgrade and apply cost-sharing — or deny it entirely. This effectively forces women to choose between their ACA-covered 2D mammogram and paying out-of-pocket for the superior 3D technology.

Many states have enacted laws requiring insurers to cover 3D mammography at no cost-sharing as the standard screening mammogram. If you live in one of these states — including California, Illinois, New York, Texas, and many others — your insurer cannot charge you a cost-share for the 3D component.

Even in states without specific 3D mammography laws, if your facility consistently uses 3D mammography as its standard screening technology, the argument can be made that the 2D+3D combined study IS the screening mammogram and should be covered in full as preventive care.

Dense Breast Supplemental Screening: Ultrasound and MRI

Women with dense breasts face an additional challenge: standard mammography (even 3D) is less effective at detecting cancer in dense tissue. Supplemental screening with ultrasound or MRI may be recommended.

Supplemental Ultrasound

Automated whole-breast ultrasound (ABUS) or handheld ultrasound can detect additional cancers in women with dense breasts that were mammographically occult. Coverage varies:

• Over 38 states have dense breast notification laws, and many require coverage for supplemental screening
• ACR Appropriateness Criteria support supplemental ultrasound for women with dense breasts and additional risk factors
• If your insurer denied supplemental ultrasound following a dense breast notification, cite your state's dense breast law and ACR appropriateness criteria

Supplemental MRI

For very high-risk women — BRCA carriers, prior chest radiation, greater than 20% lifetime breast cancer risk — annual breast MRI in addition to mammography is the standard of care per ACR and NCCN guidelines.

Insurance coverage for screening breast MRI varies by plan. For BRCA carriers, breast MRI should be covered as medically necessary screening. If your screening MRI was denied, appeal with:

• Documentation of BRCA mutation status or risk assessment showing >20% lifetime risk
• ACR Appropriateness Criteria supporting MRI screening for high-risk women
• NCCN hereditary breast/ovarian cancer guidelines

BRCA-Specific Screening Considerations

Women with BRCA1 or BRCA2 mutations face a lifetime breast cancer risk of 50–85%. For these patients, the standard of care includes:

• Annual mammography starting at 25–30 years of age
• Annual breast MRI starting at 25–30 years of age
• Consideration of risk-reducing surgical options

If your insurer is denying annual mammograms for a BRCA carrier who is under 40 (before the typical ACA screening age), appeal citing ACR guidelines and NCCN hereditary breast and ovarian cancer guidelines that specifically address high-risk screening protocols.

How to Appeal a 3D Mammography Denial

Step 1: Determine the specific denial reason. Is the 3D add-on code (77063) being denied as not covered, or being subjected to cost-sharing?

Step 2: Check your state law. Look up whether your state requires coverage of 3D mammography or supplemental dense breast screening.

Step 3: Cite the ACR's position. The ACR supports 3D mammography as the current standard for mammographic screening.

Step 4: For dense breast denials. Document your dense breast classification from your mammography report (usually reported as C or D density per BI-RADS), cite your state's dense breast notification law, and request coverage for supplemental screening.

Step 5: For high-risk patients (BRCA, >20% lifetime risk). Provide genetic testing results or risk assessment documentation and cite NCCN and ACR high-risk screening guidelines.

Step 6: File internally and escalate. External Independent Review: Complete Guide" class="auto-link">External review is particularly effective for technology-related denials where clinical evidence supporting coverage is strong.

Key Takeaways

• 3D mammography (DBT) detects significantly more cancers than 2D alone and is the ACR-preferred screening method
• Many insurers improperly charge cost-sharing for the 3D "add-on" code
• Many states mandate coverage of 3D mammography and supplemental dense breast screening
• BRCA carriers and high-risk women are entitled to more frequent and intensive screening per clinical guidelines
• State law and ACR/NCCN guidelines are your strongest appeal tools

Fight Back With ClaimBack

ClaimBack helps you identify whether your state mandates 3D mammography or dense breast supplemental screening coverage and generates a targeted appeal letter using ACR and NCCN guidelines.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied